Leaving Academia (2.2.24)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week we discuss hipsters undergoing hip replacement, pregnancy outcomes in RA and the future of academic clinicians.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week we discuss hipsters undergoing hip replacement, pregnancy outcomes in RA and the future of academic clinicians.
Somewhere between 24 and 50 million Americans have an autoimmune disease, a condition in which the immune system attacks our own tissues. As many as 4 out of 5 of those people are women.
US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.
A cross-sectional survey of academic physicians shows that approximately one-third intend to leave their institutions in the next two years. Burnout, lack of professional fulfillment, and other personal and organizational factors were associated with intention to leave.
A new study has found that the brain system enabling us to inhibit our own pain changes with age, and that gender-based differences in those changes may lead females to be more sensitive to moderate pain than males as older adults.
Ultrasound subclinical synovitis is found in a third of individuals at risk of rheumatoid arthritis (RA) patients; in half of these, subclinical synovitis resolves with a favorable outcome.
Low back pain is a major cause of disability around the globe, with more than 570 million people affected. In the United States alone, health care spending on low back pain was $134.5 billion between 1996 and 2016, and costs are increasing.
Knee osteoarthritis (OA) pain was worse with a pro-inflammatory diet, an observational study suggested.
The RECOVERY trial focused on pediatric MIS-C patients treated with immunomodulators and anti-cytokine therapy demonstrated the benefits of first-line therapy with intravenous methylprednisolone or second-line tocilizumab in children refractory to initial treatment.